Matches in UGent Biblio for { <https://biblio.ugent.be/publication/4222072#aggregation> ?p ?o. }
Showing items 1 to 60 of
60
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B678853.
- aggregation creator B678854.
- aggregation creator B678855.
- aggregation creator B678856.
- aggregation creator B678857.
- aggregation creator B678858.
- aggregation creator B678859.
- aggregation creator B678860.
- aggregation creator B678861.
- aggregation creator B678862.
- aggregation creator B678863.
- aggregation creator B678864.
- aggregation creator B678865.
- aggregation creator B678866.
- aggregation creator B678867.
- aggregation creator B678868.
- aggregation creator B678869.
- aggregation creator B678870.
- aggregation creator B678871.
- aggregation creator B678872.
- aggregation creator B678873.
- aggregation creator B678874.
- aggregation creator B678875.
- aggregation creator B678876.
- aggregation creator B678877.
- aggregation creator B678878.
- aggregation creator B678879.
- aggregation creator B678880.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 4222072.bibtex.
- aggregation hasFormat 4222072.csv.
- aggregation hasFormat 4222072.dc.
- aggregation hasFormat 4222072.didl.
- aggregation hasFormat 4222072.doc.
- aggregation hasFormat 4222072.json.
- aggregation hasFormat 4222072.mets.
- aggregation hasFormat 4222072.mods.
- aggregation hasFormat 4222072.rdf.
- aggregation hasFormat 4222072.ris.
- aggregation hasFormat 4222072.txt.
- aggregation hasFormat 4222072.xls.
- aggregation hasFormat 4222072.yaml.
- aggregation isPartOf urn:issn:0098-7484.
- aggregation language "eng".
- aggregation rights "I have retained and own the full copyright for this publication".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial".
- aggregation abstract "Importance: Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response. Objective: To determine if eritoran, a TLR4 antagonist, would significantly reduce sepsis-induced mortality. Design, Setting, and Participants: We performed a randomized, double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in September 2011. Interventions: Patients with severe sepsis (n=1961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2: 1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n=1304 and n=657 patients, respectively. Main Outcome Measures: The primary end point was 28-day all-cause mortality. The secondary end points were all-cause mortality at 3, 6, and 12 months after beginning treatment. Results: Baseline characteristics of the 2 study groups were similar. In the modified intent-to-treat analysis (randomized patients who received at least 1 dose) there was no significant difference in the primary end point of 28-day all-cause mortality with 28.1% (366/1304) in the eritoran group vs 26.9% (177/657) in the placebo group (P=.59; hazard ratio, 1.05; 95% CI, 0.88-1.26; difference in mortality rate, -1.1; 95% CI, -5.3 to 3.1) or in the key secondary end point of 1-year all-cause mortality with 44.1% (290/657) in the eritoran group vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P=.79 (hazard ratio, 0.98; 0.85-1.13). No significant differences were observed in any of the prespecified subgroups. Adverse events, including secondary infection rates, did not differ between study groups. Conclusions and Relevance: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality. Trial Registration: clinicaltrials.gov Identifier: NCT00334828".
- aggregation authorList BK1043348.
- aggregation endPage "1162".
- aggregation issue "11".
- aggregation startPage "1154".
- aggregation volume "309".
- aggregation aggregates 4222102.
- aggregation isDescribedBy 4222072.
- aggregation similarTo jama.2013.2194.
- aggregation similarTo LU-4222072.